Outlook Therapeutics, Inc. Expected to Earn FY2024 Earnings of ($4.04) Per Share (NASDAQ:OTLK)

Outlook Therapeutics, Inc. (NASDAQ:OTLK) – HC Wainwright upped their FY2024 earnings estimates for shares of Outlook Therapeutics in a research note issued on Thursday, August 15th. HC Wainwright analyst D. Tsao now anticipates that the company will earn ($4.04) per share for the year, up from their prior forecast of ($4.26). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Outlook Therapeutics’ current full-year earnings is ($4.08) per share. HC Wainwright also issued estimates for Outlook Therapeutics’ Q4 2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.99) EPS, Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($2.24) EPS and FY2026 earnings at ($0.41) EPS.

Separately, Chardan Capital restated a “buy” rating and set a $53.00 price objective on shares of Outlook Therapeutics in a research note on Friday, August 16th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $45.55.

Outlook Therapeutics Stock Performance

NASDAQ OTLK opened at $7.10 on Monday. The firm has a market capitalization of $166.21 million, a price-to-earnings ratio of -0.62 and a beta of 0.71. Outlook Therapeutics has a one year low of $4.00 and a one year high of $29.20. The company’s 50 day moving average price is $7.68 and its 200 day moving average price is $8.05.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Great Point Partners LLC raised its stake in shares of Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Rosalind Advisors Inc. raised its position in shares of Outlook Therapeutics by 44.3% during the 2nd quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after buying an additional 138,225 shares in the last quarter. LVW Advisors LLC acquired a new stake in shares of Outlook Therapeutics in the 2nd quarter worth approximately $352,000. Susquehanna Fundamental Investments LLC bought a new position in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Finally, Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics in the second quarter valued at approximately $232,000. Institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.